[go: up one dir, main page]

AR023058A1 - Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos - Google Patents

Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos

Info

Publication number
AR023058A1
AR023058A1 ARP990105306A ARP990105306A AR023058A1 AR 023058 A1 AR023058 A1 AR 023058A1 AR P990105306 A ARP990105306 A AR P990105306A AR P990105306 A ARP990105306 A AR P990105306A AR 023058 A1 AR023058 A1 AR 023058A1
Authority
AR
Argentina
Prior art keywords
cell
procedure
obtaining
preparation
pharmaceutical compositions
Prior art date
Application number
ARP990105306A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR023058A1 publication Critical patent/AR023058A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/48Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de tiazol que comprenden compuestos de formula (1), así como las sales y ésteres farmacéuticamente aceptables de los mismos, en donde R1, R2 y R3tienen el significado dado en la memoria. Inhiben la union de las proteínas adhesivas a la superficie de diferentes tipos de células y en consecuencia influyensobre las interacciones célula-célula y célula-matriz. También se describen composiciones farmacéuticas para el control o prevencion de neoplasmas, metástasisde tumores, crecimiento tumoral, osteoporosis, enfermedad de Paget, retinopatía diabética, degeneracion macular, restenosis después de una intervencionvascular, psoriasis, artitris, fibrosis, deficiencia renal, así como infecciones causadas por virus, bacterias u hongos, un procedimiento para su obtencion yel empleo de los mismos para la preparacion de medicamentos.
ARP990105306A 1998-10-22 1999-10-20 Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos AR023058A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98119985 1998-10-22

Publications (1)

Publication Number Publication Date
AR023058A1 true AR023058A1 (es) 2002-09-04

Family

ID=8232838

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105306A AR023058A1 (es) 1998-10-22 1999-10-20 Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos

Country Status (31)

Country Link
US (1) US6297266B1 (es)
EP (1) EP1123283B1 (es)
JP (1) JP3530137B2 (es)
KR (1) KR100469219B1 (es)
CN (1) CN1211375C (es)
AR (1) AR023058A1 (es)
AT (1) ATE266012T1 (es)
AU (1) AU760219B2 (es)
BR (1) BR9914666A (es)
CA (1) CA2347741C (es)
CO (1) CO5150186A1 (es)
CZ (1) CZ20011395A3 (es)
DE (1) DE69917058T2 (es)
DK (1) DK1123283T3 (es)
ES (1) ES2221482T3 (es)
HK (1) HK1047281A1 (es)
HR (1) HRP20010275A2 (es)
HU (1) HUP0104202A3 (es)
ID (1) ID28356A (es)
IL (1) IL142090A0 (es)
MA (1) MA26756A1 (es)
NO (1) NO20011908L (es)
NZ (1) NZ510676A (es)
PE (1) PE20001116A1 (es)
PL (1) PL347427A1 (es)
PT (1) PT1123283E (es)
RU (1) RU2214404C2 (es)
TR (1) TR200101115T2 (es)
WO (1) WO2000024724A1 (es)
YU (1) YU29201A (es)
ZA (1) ZA200102653B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
HUP0202708A3 (en) * 1999-04-15 2004-12-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
ES2287096T3 (es) * 2000-01-19 2007-12-16 Synvista Therapeutics, Inc. Compuestos de tiazol, imidazol y oxazol y tratamientos de trastornos asociados con el envejecimiento de las proteinas.
CA2419820A1 (en) 2000-08-17 2002-02-21 Lumera Corporation Design and synthesis of advanced nlo materials for electro-optic applications
HUP0303538A2 (hu) 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
CA2580725A1 (en) * 2004-09-20 2006-03-30 4Sc Ag Novel heterocyclic nf-kb inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010012793A1 (en) * 2008-08-01 2010-02-04 Bayer Cropscience Sa Fungicide aminothiazole derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95548A0 (en) * 1989-09-15 1991-06-30 Fujisawa Pharmaceutical Co Thiazole derivatives,processes for the preparation thereof and pharmaceutical composition containing the same
US5273982A (en) 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
JPH0987237A (ja) * 1995-09-21 1997-03-31 Kyowa Hakko Kogyo Co Ltd 芳香族誘導体
WO1997037655A1 (en) 1996-04-10 1997-10-16 Merck & Co., Inc. αvβ3 ANTAGONISTS
PL330915A1 (en) 1996-06-28 1999-06-07 Merck Patent Gmbh Phenylaniline derivatives as inhibitors of integrin
SI0928793T1 (en) * 1998-01-02 2002-10-31 F. Hoffmann-La Roche Ag Thiazole derivatives
US6100282A (en) 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6001855A (en) 1998-01-02 1999-12-14 Hoffman-La Roche Inc. Thiazole derivatives
EP0928790B1 (en) * 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Thiazole derivatives

Also Published As

Publication number Publication date
NZ510676A (en) 2003-06-30
HK1047281A1 (zh) 2003-02-14
CA2347741C (en) 2006-12-12
TR200101115T2 (tr) 2002-01-21
ES2221482T3 (es) 2004-12-16
CN1359381A (zh) 2002-07-17
CZ20011395A3 (cs) 2001-08-15
HUP0104202A2 (hu) 2002-03-28
JP3530137B2 (ja) 2004-05-24
NO20011908D0 (no) 2001-04-18
DK1123283T3 (da) 2004-09-13
CO5150186A1 (es) 2002-04-29
ID28356A (id) 2001-05-17
HRP20010275A2 (en) 2002-06-30
IL142090A0 (en) 2002-03-10
NO20011908L (no) 2001-04-18
US6297266B1 (en) 2001-10-02
PT1123283E (pt) 2004-09-30
AU1151900A (en) 2000-05-15
EP1123283A1 (en) 2001-08-16
ZA200102653B (en) 2002-07-01
BR9914666A (pt) 2001-07-17
DE69917058T2 (de) 2005-04-07
DE69917058D1 (de) 2004-06-09
YU29201A (sh) 2005-06-10
ATE266012T1 (de) 2004-05-15
PL347427A1 (en) 2002-04-08
CN1211375C (zh) 2005-07-20
MA26756A1 (fr) 2004-12-20
EP1123283B1 (en) 2004-05-06
KR20010080243A (ko) 2001-08-22
HUP0104202A3 (en) 2003-12-29
KR100469219B1 (ko) 2005-02-07
RU2214404C2 (ru) 2003-10-20
WO2000024724A1 (en) 2000-05-04
JP2002528442A (ja) 2002-09-03
AU760219B2 (en) 2003-05-08
CA2347741A1 (en) 2000-05-04
PE20001116A1 (es) 2000-10-27

Similar Documents

Publication Publication Date Title
AR024703A1 (es) Benzazepinonas y quinazolinas
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
BR9900006A (pt) Novos derivados de tiazol.
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR0112224A (pt) Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0100178A2 (hu) Tetrahidro-naftiridinil-imidazolidinil-karbonsav-származékok és ezeket tartalmazó gyógyszerkészítmények
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BR0309758A (pt) Tiazolidinonas e seu uso como inibidortes de cinase semelhante a polo
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
AR014417A1 (es) LA SAL DE BISULFATO DEL ÉSTER DIMETíLICO DEL ÁCIDO[3S- (3R*, 8'R*, 9'R*, 12R*)] -3,12-BIS (1,1-DIMETILETIL) -8- HIDROXI-4,11- DIOXO-9- (FENILMETIL) -6- [[4-(2-PIRIDINIL) -FENILMETIL]] -2,5,6,10,13- PENTAAZATETRADECANODIOICO Y LA COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE
ES2190396T3 (es) Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0209774A (pt) Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
DE602005008065D1 (de) Von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
BR0207731A (pt) Formulação cosmética compreendendo derivados de flavonóide
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
AR023058A1 (es) Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos
BR9801150A (pt) Derivados de propanolamina, processos para a preparação deles, produtos farmacêuticos compreendendo esses compostos e uso dos mesmos.
UY31544A1 (es) Compuestos que potencian el receptor de ampa y usos de los mismos en medicina
AR022542A1 (es) Derivados de piperidina y piperazina
BR0309014A (pt) ácido(2-((2-alcóxi)-fenil)-ciclopent-1-enil)carbo e heterocìclico aromático e derivados
ATE502922T1 (de) Matrix-metalloproteinaseinhibitoren
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
BRPI0507321A (pt) derivados de 7-amino-4-quinolona-3-ácido carboxìlico substituìdos com cicloalquila, processos para produção dos mesmos e uso dos mesmos como medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal